ÂÜÀòÂÒÂ×

Andrew Alexander has over 25 years’ experience in the pharmaceutical, biotech, veterinary, and medical device development and testing and the evaluation and commercialization of life science products.

Andrew has expertise in a broad range of scientific and medical disciplines including toxicology, molecular biology, immunology, oncology, diabetes, immunotherapy, biologics, medical device validation, biomarkers, R&D, translational research, allogeneic cancer vaccines, intravascular and intrathecal drug delivery, and intravascular medical devices.

Dr. Alexander holds degrees in Veterinary Medicine and Surgery, a Ph.D. in Biomolecular Science, and completed a post-doctoral fellowship in Oncology and Immunology. He holds an MBA from the University of Wisconsin with a focus on drug and medical device development, he is a Diplomate of the American Board of Toxicology (DABT), and a member of Beta Gamma Sigma, International Honor Society for Business Scholars.

Prior to joining Lumoptik, Andrew served as Senior Commerical Scientist at a Covance Laboratories where he served as study director for over 135 preclincal drug and medical device studies for FDA submission, and a mult-national infusion specialty business unit that routinely exceeded business objectives and experienced double-digit annual growth rates and $20M in revenues.